US FDA Actions On Rx Drug Promos Covered New Territory Last Year
Executive Summary
Office of Prescription Drug Promotion issued just six letters citing companies for improper drug promotion in 2020, including the placement of safety information in an email and making unfounded COVID-19 claims. New research projects focus on celebrity endorsements, medical conference materials.
You may also be interested in...
Star Power: How Celebrity Endorsement Is Shaping Pharma In India
Pharma in India draws on celebrity endorsement to spotlight specific disease conditions, with social media adding new dimensions to these efforts. But do these campaigns, now facing increasing disclosure scrutiny more widely, deliver a return on investment?
Star Power: How Celebrity Endorsement Is Shaping In India Pharma
Pharma in India draws on celebrity endorsement to spotlight specific disease conditions, with social media adding new dimensions to these efforts. But do these campaigns, now facing increasing disclosure scrutiny more widely, deliver a return on investment?
Despite Few Actions On Rx Drug Promos, US FDA Increased Engagement With Stakeholders Last Year
Office of Prescription Drug Promotion issued six enforcement letters and launched three research projects in 2021. There were more internal changes as the office switched to electronic submissions of promotional materials and went through year-end reorganization.